Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.55 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 10/20 | 0.50 |
| ▸ | F5 | P12259 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350945 | 0.84 | MAPT (0.65) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL22171703 | 0.81 | KMT2A (0.54) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL16029793 | 0.79 | GSK3A (0.58) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL31358800 | 0.79 | KMT2A (0.60) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL6589648 | 0.78 | MAPT (0.59) | ALDH1A1KMT2AMEN1HPGDCYP1A2 | |
| SCHEMBL2262163 | 0.78 | MAPT (0.63) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL2322204 | 0.77 | KMT2A (0.61) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL14999171 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL14991099 | 0.75 | ALDH1A1 (0.66) | ALDH1A1KMT2AMEN1HPGDPKM | |
| SCHEMBL5737262 | 0.75 | MAPT (0.58) | ALDH1A1KMT2AMEN1HPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110862383-A | Histone acetyltransferase P300 small-molecule inhibitor, medicinal composition thereof and application thereof | 复旦大学 | 2020-03-06 | — | — | CN | disclosed |
| US-9138439-B2 | Methods and compositions for modulating P300/CBP activity | THE WISTAR INSTITUTE (US) | 2015-09-22 | — | — | US | disclosed |
| US-9005670-B2 | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005670-B2 | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130345267-A1 | METHODS AND COMPOSITIONS FOR MODULATING P300/CBP ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-12-26 | — | — | US | disclosed |
| US-8476458-B2 | Methods and compositions for modulating P300/CBP activity | THE WISTAR INSTITUTE (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2011085039-A2 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100216853-A1 | Methods and Compositions for Modulating P300/CBP Activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216853-A1 | Methods and Compositions for Modulating P300/CBP Activity | EP300, CREBBP, HDAC1 | ALDH1A1 2328/4885KMT2A 252/4885MEN1 2982/4885 |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | EP300, HDAC1, KAT2A | ALDH1A1 677/4885KMT2A 60/4885MEN1 3023/4885 |
| US-20130345267-A1 | METHODS AND COMPOSITIONS FOR MODULATING P300/CBP ACTIVITY | EP300, CREBBP, HDAC1 | ALDH1A1 2328/4885KMT2A 252/4885MEN1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.